Biopharma plastics market seen reaching $14.9 billion by 2032

Allied Market Research projects the global biopharma plastics market will grow from $5.0 billion in 2022 to $14.9 billion by 2032, driven by demand from biopharmaceutical manufacturing and sustainable packaging. Asia-Pacific led the market in 2022, while PTFE and syringes held the largest shares in their categories.

Why it matters: - The biopharma plastics market is tied to drug manufacturing, packaging and delivery systems that need biocompatibility, chemical resistance and stability for sensitive biologics. - Market growth also reflects rising demand for sustainable packaging and recyclable materials in biopharmaceutical supply chains. - The forecast points to long-term expansion in a sector that supports sterile, high-performance medical products.

What happened: - Allied Market Research said the global biopharma plastics industry was valued at $5.0 billion in 2022 and is projected to reach $14.9 billion by 2032. - The market is expected to grow at a compound annual growth rate of 11.6% from 2023 to 2032. - The report covers polymers including polyethylene, polypropylene, acrylonitrile butadiene styrene, polyethylene terephthalate, polyvinyl chloride, polytetrafluoroethylene and others. - The report also tracks applications including protective wear, containers, bioreactor bags, syringes, depth filters and disposable medical connectors. - Leading market players include BASF SE, SABIC, Dow Inc., Covestro AG, Formosa Plastics Corporation, Solvay, Toray Industries, LyondellBasell Industries Holdings B.V., Mitsui and Co. Plastics Ltd. and INEOS Group.

The details: - Polytetrafluoroethylene held the largest polymer share in 2022, with more than two-fifths of global revenue. - PTFE is used for tubing, containers, filters and chromatography components because of its inert and biocompatible properties. - Polyethylene terephthalate is projected to post the fastest polymer CAGR at 12.5% from 2023 to 2032. - PET is used in bottles, vials, syringes and containers, and its barrier properties help protect products from moisture and oxygen. - The syringes segment held more than one-fourth of global revenue in 2022. - Syringes made with biopharma plastics support pre-filled syringes, auto-injectors and safety syringes. - Disposable medical connectors are projected to record the fastest application CAGR at 12.5% during the forecast period. - Asia-Pacific held more than one-third of global revenue in 2022. - Asia-Pacific is projected to post the fastest regional CAGR at 11.9% through the forecast period. - The report links Asia-Pacific growth to expanding pharmaceutical and biotechnology industries, healthcare infrastructure investment and higher R&D spending.

Between the lines: - The market is benefiting from two overlapping shifts: more biologic drugs and more pressure to use packaging and components that are durable, sterile and recyclable. - High material costs remain a drag on adoption. - The Russia-Ukraine war disrupted raw material supply chains, pricing and availability, especially because Russia and Ukraine are major petrochemical suppliers. - Trade restrictions and sanctions also created competitive openings for non-Russian suppliers while adding uncertainty to global trade. - The conflict has slowed regional R&D investment by diverting resources and raising geopolitical risk.

What's next: - The report expects PTFE to keep its lead through 2032. - The syringes segment is expected to remain the largest application by 2032. - Asia-Pacific is expected to keep its regional lead by 2032. - Ongoing product launches, collaborations, expansion, joint ventures and agreements are likely to remain the main competitive strategies among market players. - More information is available in the full report.